Psoriasis Uncovered Ep. 250 "The Future of Psoriasis Care: Dr. Mona Shahriari Breaks Down New AAD Research & Personalized Treatments"
Apr 29, 2025
Join Dr. Mona Shahriari, an Associate Clinical Professor of Dermatology at Yale University and co-founder of Central Connecticut Dermatology, as she reveals the latest breakthroughs from the 2025 AAD Annual Meeting. She discusses head-to-head trials comparing IL-17 and IL-23 inhibitors and emphasizes the importance of personalized therapy for psoriasis. Dr. Shahriari also highlights innovations in treating challenging areas like the scalp and nails, the role of GLP-1 medications, and how early intervention can significantly impact patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
IL-17s Outperform TNF Inhibitors
- Head-to-head trials show IL-17 inhibitors like ixekizumab outperform TNF inhibitors for joint and skin psoriasis.
- IL-17s act faster than IL-23s, especially in early skin clearance, making them better for rapid results.
Treat High-Impact Psoriasis Areas
- For difficult high-impact areas like scalp and palms, IL-17 is first line, followed by IL-23 or oral JAK inhibitors.
- Consider patient safety, for example avoid IL-17 with uncontrolled inflammatory bowel disease.
Treat Nail and Genital Psoriasis
- For nail psoriasis, start with IL-17, preferably bimikizumab, and screen for psoriatic arthritis.
- For genital psoriasis, consider topical options but have a low threshold for systemic IL-17 therapy due to psychosocial impact.